Table 1.

The effects of signaling path-ways inhibitors on MMe

Signaling	Inhibitor	Effect	Refs.
HH signaling	HhAntag (SMO antagonist)	35% ↓tumor volume and 32% ↓YAP protein and ↓SOX2 and survivin, ↓tumor growth	[14]
	Vismodegib	Gli1↓, Hhip↓, Ptch1↓, ↓tumor growth and ↓proliferation	[17]
	GDC-0449	↓proliferation	[19]
	GANT61	↓proliferation	[19]
	Cyclopamine	GLI1↓, PTCH1↓, SHH↓, SMO↓, and ↓proliferation	[20]
PI3K/mTOR signaling	BEZ235	↓cell viability and ↓proliferation	[27]
	Apitolisib with Platinum-pemetrexed chemotherapy	↓tumor volume, ↓symptoms, ↓CA-125	[28]
	BEZ235 and BYL719 with palbociclib	↓proliferation and↑ cellular senescence	[32]
	NVP-BEZ235 and GDC-0980 with Chloroquine	↓autophagy and ↓ cell death resistance	[33]
MAPK/ERK signaling and AKT/mTOR signaling	Pirfenidone alone or with cisplatin	↓proliferation	[42]